Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Health Care

Health Care

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News

What’s Going On With Candel Therapeutics Stock On Friday?

By Vandana Singh
April 5, 9:22 AM
Candel Therapeutics sees surge in shares amid robust volume, buoyed by promising interim data from CAN-2409 phase 2 trial for non-metastatic prostate cancer. Exciting developments continue with updated data from ongoing phase 1b trial of CAN-3110 for recurrent high-grade glioma

CADL

Read More
2 minute read
  • General
  • Health Care
  • Large Cap
  • M&A
  • News

Johnson & Johnson Makes Yet Another Multi-Billion MedTech Deal With Shockwave Medical

By Vandana Singh
April 5, 8:35 AM
Johnson & Johnson to acquire Shockwave Medical for $335.00/share in cash, bolstering its cardiovascular intervention portfolio. The acquisition, expected to close by mid-2024, signifies Johnson & Johnson's strategic focus on innovation and market expansion.

JNJ

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • Movers
  • News
  • Trading Ideas

Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge

By Vandana Singh
April 4, 2:32 PM
Delaware Judge favors Arbutus and Genevant Sciences in their patent dispute with Moderna over COVID-19 vaccine technology.

ABUS

Read More
1 minute read
  • Biotech
  • Equities
  • General
  • Health Care
  • Large Cap
  • Movers
  • News

Why Is Novartis Stock Trading Higher On Thursday?

By Vandana Singh
April 4, 2:09 PM
Novartis to file Pluvicto pre-taxane label expansion in 2H 2024 based on Phase 3 PSMAfore study data. Updated overall survival results show HR<1.0 in ITT population. rPFS consistent. Safety profile remains stable.

NVS

Read More
2 minute read
  • Earnings
  • General
  • Guidance
  • Health Care
  • Movers
  • News
  • Trading Ideas

Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus

By Vandana Singh
April 4, 1:54 PM
STAAR Surgical reports Q1 2024 net sales surpassing $77 million, with U.S. ICL sales hitting $5 million, the highest since FDA approval in 2022. CEO anticipates fiscal 2024 sales expected at the higher end of $335-340 million outlook.

STAA

Read More
2 minute read
  • Earnings
  • FDA
  • General
  • Guidance
  • Health Care
  • Movers
  • News

Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars

By Vandana Singh
April 4, 12:53 PM
FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. Expanded indication broadens treatment options. Sales slightly below consensus, but pro forma basis sees growth.

ANGO

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • News

CureVac, GS Partner Release Data On Influenza Vaccine Study

By Vandana Singh
April 4, 12:18 PM
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A strains prompt further optimization for influenza B strains.

BNTX

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News

Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data

By Vandana Singh
April 4, 10:38 AM
eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib shows modest activity, but no clear path forward. Zotatifin emerges as a potential candidate for ER+ breast cancer trials.

EFTR

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News

After Brain Cancer Data, Candel Therapeutics’ Shares Good News From Pancreatic Cancer Study

By Vandana Singh
April 4, 10:24 AM
Candel Therapeutics updates phase 2 trial results for CAN-2409 and valacyclovir in pancreatic cancer treatment, revealing prolonged survival rates up to 28.8 months versus standard therapy's 12.5 months.

CADL

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Technicals
  • Top Stories
  • Trading Ideas

Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead

By Surbhi Jain
April 4, 9:34 AM
Moderna stock falls 2.32% due to patent infringement suit. However, some investors see this as an opportunity to enter or average out. Golden Cross formation also offers hope for future growth.

ABUS

Posts pagination

Previous 1 … 46 47 48 … 478 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service